Literature DB >> 33632339

Sex-dependent liver cancer xenograft models for predicting clinical data in the evaluation of anticancer drugs.

Sungryong Oh1, Joohee Jung2.   

Abstract

BACKGROUND: The incidence and mortality of liver cancer show a great difference between the sexes. We established sex-dependent liver cancer xenograft models and investigated whether such sex-dependent models could be used to simultaneously evaluate the therapeutic and adverse effects of anticancer drugs for drug screening.
RESULTS: In the in-vitro test, the cytotoxicity of anticancer drugs (cisplatin, 5-fluorouracil, and doxorubicin) was compared between male- and female-derived liver cancer cell lines. Cisplatin and 5-fluorouracil exhibited cytotoxicity without sex-difference, but doxorubicin showed dose-dependently significant cytotoxicity only in male-derived cells. Our results showed a strong correlation between preclinical and clinical data with the use of sex-dependent liver cancer xenograft models. Moreover, the male-derived Hep3B-derived xenograft model was more sensitive than the female-derived SNU-387-derived xenograft model against doxorubicin treatment. Doxorubicin showed more severe cardiotoxicity in the male xenograft model than in the female model. We investigated the occurrence frequency of doxorubicin-related cardiotoxicity using data obtained from the Korea Institute of Drug Safety & Risk Management Database, but no significant difference was observed between the sexes.
CONCLUSIONS: Our results suggest that sex-dependent xenograft models are useful tools for evaluating the therapeutic and adverse effects of anticancer drugs, because sex is an important consideration in drug development.

Entities:  

Keywords:  Cardiotoxicity; Doxorubicin; Liver cancer; Sex difference; The Korea Institute of Drug Safety & risk management database; Xenograft model

Year:  2021        PMID: 33632339     DOI: 10.1186/s42826-021-00087-z

Source DB:  PubMed          Journal:  Lab Anim Res        ISSN: 1738-6055


  6 in total

1.  Hepatocellular carcinoma: gender differences.

Authors:  Sarah Seton-Rogers
Journal:  Nat Rev Cancer       Date:  2014-08-14       Impact factor: 60.716

2.  Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.

Authors:  O J Arola; A Saraste; K Pulkki; M Kallajoki; M Parvinen; L M Voipio-Pulkki
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

3.  Doxorubicin cardiotoxicity in the rat: an in vivo characterization.

Authors:  Reid Hayward; David S Hydock
Journal:  J Am Assoc Lab Anim Sci       Date:  2007-07       Impact factor: 1.232

4.  Virosomes of hepatitis B virus envelope L proteins containing doxorubicin: synergistic enhancement of human liver-specific antitumor growth activity by radiotherapy.

Authors:  Qiushi Liu; Joohee Jung; Masaharu Somiya; Masumi Iijima; Nobuo Yoshimoto; Tomoaki Niimi; Andrés D Maturana; Seol Hwa Shin; Seong-Yun Jeong; Eun Kyung Choi; Shun'ichi Kuroda
Journal:  Int J Nanomedicine       Date:  2015-06-25

Review 5.  Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action.

Authors:  Saad Shaaban; Amr Negm; Elsayed E Ibrahim; Ahmed A Elrazak
Journal:  Oncol Rev       Date:  2014-05-28

6.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

Authors:  Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave Beare; James A Smith; I Richard Thompson; Sridhar Ramaswamy; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Cyril Benes; Ultan McDermott; Mathew J Garnett
Journal:  Nucleic Acids Res       Date:  2012-11-23       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.